Technical Name 以CXCR4受體為分子標的之急性心肌梗塞治療藥物開發
Project Operator National Health Research Institutes
Project Host 夏克山
Summary
DBPR807, a safehighly specific CXCR4-targeting antagonist, has completed the concept validation of treating acute myocardial infarction (AMI) through both ratmini-pig animal disease models induced by occluding the left anterior descending artery (LAD). When DBPR807 (5 mg/kg, SC) was given in the rat model, a significant heart-protective effect was observed with reducing cardiac infarctionfibrosis by 4341, respectively. In the mini-pig model, DBPR807 (3 mg/kg, IV) treatment was allowed to improve 3-month LVEF up to 52 falling in a standard range between 50~70.
Scientific Breakthrough
DBPR807, a safehighly specific CXCR4-targeting antagonist containing a unique oxazole 5-membered ring, was allowed to significantly reduce heart damage caused by reperfusion during PCI operation in treating AMI. DBPR807 therapeutic efficacy is superior to its Phase II counterparts TG-0054POL6326 in the mini-pig disease model with a significant improvement in the long-term prognosis up to 52 in the 3-month LVEF, a standard range of which is between 5070.
Industrial Applicability
PCI is a standard medical procedure for treating AMI, while the reperfusion of LAD occlusion during the process may cause heart damage, leading to the poor long-term prognosis. As demonstrated by the ratmini-pig disease models, treatment with DBPR807 prior to PCI has been shown to have a significant heart-protective effect, providing a potential combination therapy for AMI.
Matching Needs
天使投資人、策略合作夥伴
Keyword CXCL12 CXCR4 antagonist acute myocardial infarction percutaneous coronary intervention coronary artery left anterior descending branch Tissue hypoxia left ventricular ejection fraction combination therapy
Notes
  • Contact